Daiichi Sankyo Pharma Development, Edison, New Jersey (United States of America)
Follow
Contributor content
Presentation
Linking intrinsic factor X activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentration and clinical outcomes in the ENGAGE AF-TIMI 48 trial
